Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
USA v. Stevens
Case Number:
8:10-cr-00694
Court:
Nature of Suit:
Judge:
Firms
-
June 16, 2011
How They Won It: Steptoe Gets Rare Acquittal For GSK Atty
When prosecutors indicted former GlaxoSmithKline PLC associate general counsel Lauren Stevens on charges that she obstructed a U.S. Food and Drug Administration investigation, defense attorney Bill Hassler of Steptoe & Johnson LLP fought to move the case to trial quickly — and won.
-
May 10, 2011
GSK Atty Acquitted On All Counts In Obstruction Case
A Maryland federal judge on Tuesday acquitted former GlaxoSmithKline PLC associate general counsel Lauren Stevens of all charges of obstructing justice and lying to federal authorities in an investigation into the off-label marketing of antidepressant Wellbutrin.
-
May 09, 2011
US Can't Prove Wellbutrin Statements False: GSK Atty
Former GlaxoSmithKline PLC attorney Lauren Stevens asked a Maryland federal judge Monday to toss criminal charges of obstructing justice and lying to federal investigators in relation to an investigation of whether the company illegally marketed antidepressant Wellbutrin for weight loss purposes.
-
May 05, 2011
Doctors Were Chastised For Wellbutrin Claims: GSK Exec
GlaxoSmithKline PLC worked with physicians to stop promotion of antidepressant Wellbutrin for off-label uses, a company executive testified Thursday in the Maryland trial of a former GSK attorney who allegedly obstructed a probe into the drug's marketing.
-
May 04, 2011
Off-Label Use OK When Not Promoted, GSK Exec Says
Prescribing Wellbutrin for off-label uses is fine, GlaxoSmithKline PLC just can't promote the antidepressant for such uses, a company executive testified Wednesday in the Maryland trial of a former GSK attorney who allegedly obstructed a probe into the drug's marketing.
-
May 03, 2011
GSK Scripted Response For Wellbutrin Probe, Atty Says
GlaxoSmithKline PLC's in-house legal team planned to "script" a response to regulators if quizzed about nondisclosed information in a probe of the drugmaker's marketing of antidepressant Wellbutrin, a GSK attorney told a Washington jury Tuesday in a former colleague's trial.
-
April 20, 2011
Feds Want GSK VP To Testify In Wellbutrin Case
Prosecutors asked a Maryland federal judge Tuesday to force a GlaxoSmithKline PLC vice president to testify in the criminal case against a former GSK attorney accused of lying to health regulators about the marketing of antidepressant Wellbutrin.
-
April 14, 2011
Ex-GSK Lawyer Faces New Obstruction Indictment
Prosecutors have reindicted a former GlaxoSmithKline PLC attorney for allegedly lying to health regulators about the marketing of the antidepressant Wellbutrin, three weeks after a judge dismissed an earlier indictment for prosecutorial error, the U.S. Department of Justice said Thursday.
-
March 21, 2011
Indicted GSK Atty Says Prosecutors Misled Grand Jury
Prosecutors misled the grand jury that indicted a former GlaxoSmithKline PLC attorney for allegedly lying to regulators about off-label marketing of antidepressant Wellbutrin, the defendant said in a motion unsealed Thursday.
-
February 07, 2011
Ex-GSK Atty Wants Obstruction Charge Nixed
A former GlaxoSmithKline PLC attorney has asked a federal judge to dismiss an obstruction of justice charge relating to a federal probe of whether the drugmaker illegally marketed its antidepressant Wellbutrin SR for weight-loss purposes.